Tumor Treating Fields (TTFields) are electric fields that disrupt processes which are critical for the survival of cancer cells. This leads to immunogenic cell death and enhanced antitumor immune response. The use of Tumor treating fields with standard care therapies could lead to a clinically meaningful improvement in survival of patients with metastatic non-small cell lung cancer, according to data from a phase 3 trial. The results are from the LUNAR trial published in The Lancet Oncology.
In the phase 3 trial, the patients who received TTFields therapy and standard therapy had a 26% lower death risk when compared with patients with standard therapy alone. Median overall survival for patients in this trial was 13.2 months with TTFields plus standard care in comparison with 9.9 months with standard care only. The one and three-year overall survival rates were 53% and 18% respectively with addition of TTFields, compared to 42% and 7% in the standard of care alone. Also, there was no significant difference in progression-free survival or overall response rate between the treatment arms. Serious adverse events of any cause were 53% in TTF arm and 38% in standard therapy-alone arm.
“The overall survival benefit with TTFields [tumor-treating fields] therapy occurred without exacerbating the toxicities associated with systemic therapies,” the researchers wrote. “These pivotal efficacy and safety data suggest that TTFields therapy should be considered as a treatment option to manage the disease in this setting.”
This research was supported by Novocure. Novocure is going to participate in 2023 World Conference on Lung Cancer and will exhibit several posters exploring the use of TTFields therapy in lung cancer treatment including a new post-hoc analysis of data from the above discussed LUNAR trial in metastatic non-small cell lung cancer.
The information shared in this blog is for educational purposes only.